Asylia Announces Formation of Distinguished Scientific Advisory Board
HOUSTON, July 22, 2021 – Asylia Therapeutics (“Asylia”), a development-stage biotechnology company advancing novel immune modulating therapies for cancer and autoimmune diseases, today announced the formation of a Scientific Advisory Board (SAB) comprised of prominent experts and thought leaders in immunology and cancer biology. The formation of the SAB reflects significant progress with Asylia’s clinical …
Asylia Announces Formation of Distinguished Scientific Advisory Board Read More »